Conventional Trials Can't Detect Heterogeneity in BP Tx Effects

Share this content:
Conventional Trials Can't Detect Heterogeneity in BP Tx Effects
Conventional Trials Can't Detect Heterogeneity in BP Tx Effects

TUESDAY, Jan. 3, 2017 (HealthDay News) -- Conventional clinical trials are unable to detect clinically important heterogeneity in intensive blood pressure (BP) treatment effects, according to a modeling study published online Jan. 3 in the Annals of Internal Medicine.

Sanjay Basu, M.D., Ph.D., from Stanford University in Palo Alto, Calif., and colleagues performed a theoretical modeling study in a population of U.S. adults to identify whether large, clinically important differences in benefit and harm can be hidden among patients (heterogeneous treatment effects [HTEs]) in BP trials. The authors used data from two trials comparing standard with intensive BP treatment and from the National Health and Nutrition Examination Survey 2013 to 2014.

The researchers found that in base-case analysis, clinically important HTEs could explain the differences in outcomes between two trials of intensive BP treatment, with decreasing benefit with each additional agent (adding a second agent reduces cardiovascular disease risk, but adding a fourth agent had no benefit) and increasing harm at low BP. In sensitivity analyses, despite large samples, conventional treat-to-target trial designs had poor power to detect HTEs (<5 percent), and produced biased estimates. Despite small samples, a trial with sequential randomization to more intensive therapy achieved greater than 80 percent power and unbiased HTE estimates.

"Clinically important heterogeneity in intensive BP treatment effects remains undetectable in conventional trial designs but can be detected in sequential randomization trial designs," the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »